首页> 美国卫生研究院文献>AMIA Summits on Translational Science Proceedings >Coverage Evaluation of CTCAE for Capturing the Immune-related Adverse Events Leveraging Text Mining Technologies
【2h】

Coverage Evaluation of CTCAE for Capturing the Immune-related Adverse Events Leveraging Text Mining Technologies

机译:利用文本挖掘技术捕获CTCAE捕获免疫相关不良事件的覆盖范围评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Immunotherapy is seen as a promising new treatment for cancer but it may also cause immune-related adverse events (irAEs). Post-market surveillance of immunotherapy drugs highly depends on the ability to capture and standardize irAE data. The Common Terminology Criteria for Adverse Events (CTCAE) is a potential terminology that can be leveraged for irAEs standardization. However, the capability of the CTCAE in irAEs standardization needs to be evaluated. >Methods: We investigated the irAEs of six FDA approved cancer immunotherapy monoclonal antibodies (mAbs) and evaluated the coverage of the CTCAE for capturing irAEs. We manually identified irAEs from drug labels of the 6 mAbs as the gold standard. We assessed the performance of two text mining pipelines using the dictionary lookup of the CTCAE terms and identified irAEs. In the coverage evaluation, the CTCAE was compared with MedDRA, a standard terminology for regulatory science, for irAE standardization. >Results: We manually identified 510 unique irAEs from the drug labels. When using the CTCAE as a dictionary to run the text mining pipeline, the precision, recall and F-measure value was 100%, 10.78% and 19.47%. After adding manually identified irAE terms into the dictionary, the recall and F-measure value significantly improved, increased to 95.69% and 97.31%, respectively. In the coverage evaluation, compared with MedDRA, the coverage rate of the CTCAE is only 13.50% when taking all the mining results together into consideration. >Conclusion: With some limitations in our study, we clearly demonstrated that the CTCAE needs an extension to meet the irAE standardization task.
机译:>背景:免疫疗法被认为是一种有前途的癌症新疗法,但它也可能引起免疫相关的不良事件(irAEs)。免疫疗法药物的上市后监视高度依赖于捕获和标准化irAE数据的能力。不良事件通用术语标准(CTCAE)是可用于irAEs标准化的潜在术语。但是,需要评估CTCAE在irAEs标准化方面的能力。 >方法:我们研究了六种FDA批准的癌症免疫疗法单克隆抗体(mAb)的irAE,并评估了CTCAE捕获irAE的覆盖范围。我们从6 mAb的药物标签中手动鉴定了irAE,将其作为金标准。我们使用CTCAE术语的字典查找和已识别的irAE评估了两个文本挖掘管道的性能。在覆盖范围评估中,将CTCAE与MedDRA(一种用于监管科学的标准术语)进行了irAE标准化比较。 >结果:我们从药品标签中手动识别了510个独特的irAE。当使用CTCAE作为字典来运行文本挖掘管道时,精度,召回率和F量度值分别为100%,10.78%和19.47%。将手动识别的irAE术语添加到字典中后,召回率和F测量值显着提高,分别提高到95.69%和97.31%。在覆盖率评估中,与MedDRA相比,将所有挖掘结果都考虑在内,CTCAE的覆盖率仅为13.50%。 >结论:由于我们的研究存在某些局限性,我们清楚地证明了CTCAE需要扩展才能满足irAE标准化任务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号